Barentz acquires the trade assets of Biogredia

Article

The acquisition, says the company, will strengthen Barentz’ value-added product offerings, and aligns with its strategy to grow in nutraceutical markets globally.

Photo © iStockphoto.com/skyneshe

Photo © iStockphoto.com/skyneshe

Barentz International (Hoofddorp, The Netherlands) has acquired the trade assets of Biogredia (Sandefjord, Norway), according to a press release. The acquisition, says the company, will strengthen Barentz’ value-added product offerings, and aligns with its strategy to grow in nutraceutical markets globally. More specifically, the acquisition will strengthen Barentz’ European nutracetucal business line in Northern Europe, United Kingdom, and Ireland by leveraging Biogredia’s principal relationships across its European network.

Once the acquisition is complete, Biogredia’s trade assets will be integrated into the Barentz EMEA operating structure. The Biogredia trade name will continue to be used for a pre-defied period of time.

“After the acquisition of Natural Ingredients last year, we started a separate business line for Nutraceuticals,” said Hidde van der Wal, CEO of Barentz, in a press release. “Biogredia fits perfectly in the next step in our strategy. Bengt Hansson and his team believe in the same business principles as Barentz and together we will grow our position as a premium distributor in the important and attractive nutraceutical segment.”

“Our team indeed operates in line with the same business values as Barentz and their nutraceutical business approach for EMEA offers a lot of chances for further growth, together,” said Bengt Hansson, founder of Biogredia. “Our Barentz portfolio will be impressive and strong. We are looking forward to entering this new era as part of Barentz, a great global company and strong brand.”

According to the press release, Hansson will continue to play a key role in growing the business following the completion of the acquisition.

Related Videos
woman working on laptop computer by window
© 2024 MJH Life Sciences

All rights reserved.